Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice

BACKGROUND: The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness of the combination therapy with vemurafenib/cobime...

Descripción completa

Detalles Bibliográficos
Autores principales: Álamo, Mª del Carmen, Ochenduszko, Sebastian, Crespo, Guillermo, Corral, Mónica, Oramas, Juana, Sancho, Pilar, Medina, Javier, Garicano, Fernando, López, Pedro, Campos Balea, Begoña, Rodríguez Garzotto, Analia, Muñoz-Couselo, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636950/
https://www.ncbi.nlm.nih.gov/pubmed/34866914
http://dx.doi.org/10.2147/OTT.S325208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636950/
https://www.ncbi.nlm.nih.gov/pubmed/34866914
http://dx.doi.org/10.2147/OTT.S325208

Ejemplares similares